Tag: Oncoinvent AS

Announcement of fully underwritten rights issue

OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription...

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsOncoinvent AS

Alvopetro Announces June 2025 Sales Volumes

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

Aduro Clean Technologies Announces Grant of Stock Options and RSUs

Tag: Oncoinvent AS

Announcement of fully underwritten rights issue

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us